Latest News about HALO
Recent news which mentions HALO
Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune
October 27, 2023
From InvestorPlace
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
October 19, 2023
From Benzinga
7 Sleeper Stocks That Should Be on Every Investor’s Radar This Fall
September 23, 2023
From InvestorPlace
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
July 28, 2023
From Benzinga
Halozyme's Subcutaneous Drug Delivery: Analysts Initiate With 'Buy' Rating, Say Enhanze Tech Targets $41.7B Market
July 24, 2023
Tickers
HALO
From Benzinga
From Benzinga
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
July 13, 2023
From Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
June 21, 2023
From Benzinga
From Benzinga
From Benzinga
From InvestorPlace
From Benzinga
Stocks That Hit 52-Week Lows On Monday
May 08, 2023
From Benzinga
From Benzinga
5 Analysts Have This to Say About Halozyme Therapeutics
February 22, 2023
Tickers
HALO
From Benzinga
From Benzinga
Nasdaq Rises Over 1%; CommVault Systems Shares Plummet
January 11, 2023
From Benzinga
Why Broadwind Shares Are Trading Higher By 85%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 11, 2023
From Benzinga
CommVault Systems, Halozyme Therapeutics And Other Big Stocks Moving Lower On Wednesday
January 11, 2023
From Benzinga
US Stocks Open Higher; Nasdaq Rises 60 Points
January 11, 2023
From Benzinga
5 Analysts Have This to Say About Halozyme Therapeutics
December 08, 2022
Tickers
HALO
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.